US 12110492
RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use
granted A61KA61K31/712A61K47/549
Quick answer
US patent 12110492 (RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/712, A61K47/549